RUXOLITINIB PHOSPHATE

first possible commercially ready supplier

GMP SUPPLIER - US FDA APPROVAL - USDMF AVAILABLE

RUXOLITINIB PHOSPHATE (CAS 220127-57-1) is a Janus kinase inhibitor for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow. It is also approved for polycythemia vera and is being investigated for treatment of other kinds of cancer.

MARKET INFORMATION

Originator: NOVARTIS
Originator product: JAKAFI® and JAKAVI®

YOUR ADVANTAGES   

  • FDA-approved, WC available
  • Active US DMF available
  • GMP supplier

This article uses material from Wikipedia, which is released under the Creative Commons Attribution-Share-Alike License 3.0.